Copenhagen Demark – 3 June 2020. Monsenso A/S today announced the result of the new share offering in connection with the IPO on Nasdaq First North Growth Market Denmark.

Monsenso’s IPO offering was oversubscribed by 238%, which means that the company offer of DKK 16-20 million new shares was extremely well received by both professional and private investors, which together have subscribed for DKK 47,504,123, corresponding to the maximum offering.

The subscription period closed on 29 May 2020 at 23:59 hrs. CEST time. The company’s offering of up to 3,773,585 shares, at a price of DKK 5.30 per share has come to an end and will provide the company with gross proceeds of DKK 20 million and result in a market cap of DKK 70.04 million.

Monsenso received subscriptions from 2,219 investors for a total of 8,963,042 shares corresponding to the offering being oversubscribed by a total of 238%.

The first trading day on Nasdaq First North Growth Market Denmark is expected to be on 10 June 2020.

CEO Thomas Lethenborg, Monsenso said:

“The IPO offering was very well received by professional and private investors, including great participation in our online investor meetings. We have now received the necessary funding to strengthen our sales efforts, customer support, and to further develop our mHealth solution for mental health. We now have to live up to the trust and expectations coming from our 2,219 new shareholders. We look forward to being a listed company and welcoming the continued support from our many new shareholders.”

Summary of the Offer:

• Monsenso issued 3,773,585 new shares at a subscription price of DKK 5.30 per share, which gives gross proceeds of DKK 20.0 million
• Based on the offer price, Monsenso’s market cap is now DKK 70.05 million
• Free float (the proportion of the share capital owned by the new shareholders) is 27.05%
• Due to the great interest in the offering, all orders up to and including DKK 150,000 have been allocated 720 shares plus 20% of the number of shares subscribed for in addition to the 720 shares
• All orders over DKK 150,000 have been reduced individually based on the company’s assessment
• All pre-offering subscribers have received a full allocation.

For additional information contact:

Thomas Lethenborg
CEO Monsenso
lethenborg@monsenso.com

Copenhagen, Denmark – 28 April  2020 – Danish start-up Monsenso is ready for the stock exchange after continuous growth for several years, with its easily scalable and highly demanded mobile health solution for mental healthcare. The Danish start-up Monsenso has managed to deliver growth in revenue, increase its number of customers, and deliver profits.

Monsenso will now leverage this momentum and invite Danish investors on its upcoming global growth journey.

With a certified and scalable mobile health solution, Monsenso’s technology has proven to be a useful tool to achieve better mental health for more people, with significantly lower costs to society as a result.

The demand for the Monsenso mHealth solution is high, and at the same time, the competitive situation is exceptionally favourable. The Monsenso solution is clinically validated, and thus, it differs significantly from the many stand-alone apps that are available online.

Today, the Monsenso mHealth solution has been deployed to 10 different countries. Now, it has the opportunity to scale up further to more markets, as satisfied customers increase their orders, and new customers sign up.

Growth Plan

Monsenso expects to double its revenue in the coming financial year from DKK 9 million in 2020 to DKK 18.5 million in 2021, and accomplish a revenue of DKK 75 million by 2024.

With the IPO, Monsenso aims to raise a total of DKK 20 million to finance the company’s continued growth journey, expand the organization, and be able to scale up the business further in line with growing demand.

Monsenso has chosen to be admitted to trading at NASDAQ First North GM Copenhagen because broader ownership, as well as the transparency and responsibility that the acquisition entails, will make Monsenso a more attractive partner for its customers.

Corona crisis increases the need for the Monsenso mHealth solution

The current global corona crisis is increasing the demand for Monsenso’s mHealth solution because the technology provides an effective solution to the problems faced due to the isolation experienced by hundreds of thousands of people around the world.

The crisis and the accompanying quarantine measures are spurring people to embrace mobile solutions even more. Digitalization has taken a massive leap in a very short time, and mHealth solutions and well as telemedicine portals will be in high-demand.

Monsenso presents this Intention to Float, paving the way for a listing on NASDAQ First North GM in Copenhagen before summer. Monsenso’s management looks forward to this milestone for the company.

CEO Thomas Lethenborg: “Monsenso’s mHealth solution is hitting a huge and unmet global need to help treat mental disorders. With our strong research foundation and a demonstrated proof of business for private and public players, we believe that the time is right to raise funds and continue our global expansion.”

Chairman Jukka Pertola: “The corona crisis is clearly showing that mobile health solutions work well and that there is a great need in the market. When, during a crisis like corona, physical contact is not possible, mobile health solutions like Monsenso’s are needed even more. That’s why we stick to our plans for a stock exchange listing. “

CTO Jakob Bardram: “Monsenso offers clinicians an easy-to-use tool to monitor patients remotely. With continuous real-time feedback of data, treatment can be tailored for each patient; this results in a more optimal treatment at a lower cost. In the next phase, we will make the solution more scalable and increase the content of the treatment to meet increasing demand.”

Partnerships

Monsenso has entered into a long-term partnership with one of the world’s leading global pharmaceutical companies to use Monsenso’s healthcare solution to support product launches in select countries in Europe.

Monsenso also collaborates with several customers in Denmark and the UK, including the Capital Region, a number of Danish municipalities, and Exeter University.

In the coming years, Monsenso wants to expand and strengthen its market position, and constantly invest in making the solution more configurable with new treatment options, in order to meet the growing demand from more mental disorders.

For information on how to purchase stock options visit www.monsenso.com/investors/

For additional information contact:

Jennifer Highland
Marketing, Monsenso
marketing@monsenso.com